Misplaced Pages

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 05:26, 22 October 2011 (Updating {{drugbox}} (changes to verified fields - updated 'ChEBI_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report errors or bugs)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Fesoterodine

Clinical data
AHFS/Drugs.com	Monograph
MedlinePlus	a609021
License data	EU EMA: by INN US FDA: Fesoterodine
Routes of administration	Oral
ATC code	G04BD11 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	52% (active metabolite)
Protein binding	50% (active metabolite)
Metabolism	Hepatic (CYP2D6- and 3A4-mediated)
Elimination half-life	7–8 hours (active metabolite)
Excretion	Renal (70%) and fecal (7%)
Identifiers
IUPAC name -4-(hydroxymethyl)phenyl] 2-methylpropanoate
CAS Number	286930-03-8
PubChem CID	6918558
DrugBank	DB06702
ChemSpider	5293755
UNII	621G617227
KEGG	D07226
ChEMBL	ChEMBL1201764
CompTox Dashboard (EPA)	DTXSID80182853
ECHA InfoCard	100.184.854
Chemical and physical data
Formula	C26H37NO3
Molar mass	411.278 g/mol g·mol
3D model (JSmol)	Interactive image
SMILES O=C(Oc1ccc(cc1(c2ccccc2)CCN(C(C)C)C(C)C)CO)C(C)C
InChI InChI=1S/C26H37NO3/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3/t23-/m1/s1 Key:DCCSDBARQIPTGU-HSZRJFAPSA-N
(what is this?)  (verify)

Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB). It was approved by the European Medicines Agency in April 2007 and was approved by the US Food and Drug Administration on October 31, 2008.

Fesoterodine is a prodrug. It is broken down into its active metabolite, 5-hydroxymethyl tolterodine, by plasma esterases.

Efficacy

In two large, 12-week, randomized, double-blind multicentre Phase III trials, oral fesoterodine 4 or 8mg once daily improved the symptoms of OAB significantly more than placebo.

References

1. "Fesoterodine, New Drug Candidate For Treatment For Overactive Bladder – Pfizer To Acquire Exclusive Worldwide Rights". Medical News Today. 17 April 2006.
2. "Toviaz: European Public Assessment Report, Revision 3 - Published 02/06/08". European Medicines Agency. 2 June 2008.
3. "Pfizer's Toviaz (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder" (Press release). Pfizer Inc. 2008-10-31. Retrieved 2008-11-06.
4. McKeage K, Keating GM..Drugs 2009; 69(6):731-738.doi: 10.2165/00003495-200969060-00006.

This drug article relating to the genito-urinary system is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Muscarinic antagonists
• Prodrugs
• Alcohols
• Amines
• Isobutyrates
• Genito-urinary system drug stubs